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Cell growth (accumulation ofmass) needs to be coor-
dinated with metabolic processes that are required
for the synthesis of macromolecules. The PI3-ki-
nase/Akt signaling pathway induces cell growth via
activation of complex 1 of the target of rapamycin
(TORC1). Here we show that Akt-dependent lipogen-
esis requires mTORC1 activity. Furthermore, nuclear
accumulation of themature form of the sterol respon-
sive element binding protein (SREBP1) and expres-
sion of SREBP target genes was blocked by the
mTORC1 inhibitor rapamycin. We also show that si-
lencing of SREBP blocks Akt-dependent lipogenesis
and attenuates the increase in cell size in response to
Akt activation in vitro. Silencing of dSREBP in flies
caused a reduction in cell and organ size and
blocked the induction of cell growth by dPI3K. Our
results suggest that the PI3K/Akt/TOR pathway
regulates protein and lipid biosynthesis in an orches-
trated manner and that both processes are required
for cell growth.
INTRODUCTION
The serine/threonine kinase Akt (PKB/c-Akt) promotes cell
growth (i.e., accumulation of cell mass) predominantly through
activation of complex 1 of the mammalian target of rapamycin
(mTORC1) (Sarbassov et al., 2005). mTORC1 is regulated by
both nutrients and growth factors and plays a conserved role in
cell growth control (Wullschleger et al., 2006). Glucose uptake
and induction of glycolysis by Akt have been studied in the
context of the metabolic effects of insulin signaling on cellular
and organismal levels (Whiteman et al., 2002). However, the
contribution of anabolic pathways other than protein biosynthe-
sis to cell growth have only been considered recently (Plas and
Thompson, 2005).224 Cell Metabolism 8, 224–236, September 3, 2008 ª2008 ElsevierAkt regulates cell metabolism through several downstream
targets (Manning and Cantley, 2007). Akt stimulates glucose up-
take via induction of translocation of the glucose transporter 4
(GLUT4) to the plasma membrane and by increasing expression
of GLUT1 (Kohn et al., 1996; Welsh et al., 2005). Akt promotes
conversion of glucose into pyruvate through the glycolytic
pathway by increasing the expression of glycolytic enzymes (Se-
menza et al., 1996) and by phosphorylating and activating hexo-
kinase 2 (HK2) (Robey and Hay, 2006). Pyruvate can either be
converted into lactate, or it can enter the tricarboxylic acid cycle
(TCA cycle), where it is fully oxidized to generate ATP. In liver and
adipose tissue, glucose is converted via pyruvate and citrate into
lipids.
Akt activates mTORC1 through two distinct mechanisms.
Phosphorylation of TSC2 by Akt (Inoki et al., 2002; Potter et al.,
2002) results in activation of the Rheb GTPase while phosphor-
ylation of the PRAS40 induces the dissociation of this inhibitory
component from the mTORC1 complex (Oshiro et al., 2007; San-
cak et al., 2007; Vander Haar et al., 2007). There are several lines
of evidence that the Akt/mTORC1 axis is an essential regulator of
cell growth in vivo. Akt1/Akt2 double-knockout mice exhibit se-
vere growth deficiency (Peng et al., 2003) and mice deficient in
S6-kinase 1 (S6K1) show a significant reduction in size accom-
panied by hypoinsulinaemia and glucose intolerance (Pende
et al., 2004).
The family of sterol regulatory element binding proteins
(SREBP) consists of three closely related members: SREBP1a,
SREBP1c, and SREBP2 (Eberle et al., 2004). They have been
identified as mediators of the effect of sterols on expression
of enzymes involved in lipid and cholesterol homeostasis
(Yokoyama et al., 1993). SREBPs belong to the family of basic
helix-loop-helix-leucine zipper (bHLH-Zip) transcription factors.
They are synthesized as inactive precursors and localize to the
endoplasmic reticulum (ER), where they bind to the sterol cleav-
age activating protein (SCAP). The SREBP/SCAP complex binds
to COPII proteins and translocates to the Golgi where a two-step
proteolytic cleavage releases the N-terminal half of the SREBP
protein and allows entry into the nucleus (Rawson, 2003).
SREBPs bind to sterol regulatory element (SRE) and E box
sequences found in the promoter regions of genes involved inInc.
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Role of SREBP in Akt-Dependent Cell Growthcholesterol and fatty acid biosynthesis. Studies in knockout and
transgenic mice have shown that SREBP1 preferentially regu-
lates genes involved in fatty acid biosynthesis while SREBP2
mainly regulates genes of the cholesterol pathway (Horton
et al., 2003).
Two key enzymes that are required to divert glycolytic carbon
flux into lipid biosynthesis are ATP-citrate lyase (ACLY) and fatty
acid synthase (FASN). ACLY converts cytosolic citrate into ace-
tyl-CoA and oxaloacetate, thereby supplying the essential me-
tabolite for lipid biosynthesis. Akt phosphorylates ACLY (Berwick
et al., 2002), and ACLY activity is required for cell growth and tu-
morigenesis (Bauer et al., 2005; Hatzivassiliou et al., 2005). FASN
catalyzes the condensation of acetyl-CoA and malonyl-CoA to
generate long-chain fatty acids. We have previously shown that
activation of Akt induces expression of a number of lipogenic
genes, including ACLY and FASN (Porstmann et al., 2005). We
show here that activation of SREBP and Akt-dependent induction
of lipid biosynthesis requires the activity of mTORC1. Further-
more, activation of SREBP contributes to Akt-dependent cell
growth in mammalian cells in vitro and in Drosophila mela-
nogaster in vivo. Our data demonstrate the importance of
lipogenesis for cell growth in two distinct model systems.
RESULTS
Role of mTORC1 in Akt-Dependent Cell Growth
and Lipid Biosynthesis
Akt is involved in the regulation of cell growth in both mammalian
and invertebrate systems by activation of protein biosynthesis
through the mTOR/S6K pathway (Sarbassov et al., 2005). To in-
vestigate the involvement of de novo lipid biosynthesis in the reg-
ulation of cell growth by Akt, we used immortalized human retinal
pigment epithelial cells (RPE) expressing a conditional allele of
the Akt1 kinase (myrAkt-ER) (Porstmann et al., 2005). Cells
were cultured in medium supplemented with 1% lipoprotein de-
ficient serum (LPDS) to reduce activation of endogenous Akt and
limit the availability of exogenous lipids. Activation of myrAkt-ER
by addition of 4-hydroxytamoxifen (4-OHT) caused a 20%–30%
increase in median cell volume (MCV) (Figures 1A and 1B). Simul-
taneous treatment with the specific mTORC1 inhibitor rapamy-
cin abolished the Akt-dependent increase in cell volume. Rapa-
mycin did not affect cell size in the absence of Akt activation
since the experiment was performed under serum starvation
conditions. However, rapamycin markedly reduced the Akt-de-
pendent increase in cellular protein content (Figure S1). Impor-
tantly, we did not observe significant changes in cell-cycle distri-
bution upon Akt activation under the conditions used here (data
not shown).
We next used nuclear magnetic resonance spectroscopy
(NMR) to measure changes in medium metabolite concentration
before and after myrAkt-ER activation. Akt activation induced an
almost 2-fold increase in glucose uptake and lactate production
in RPE cells (Figure 1C) consistent with a role for Akt in activation
of glucose uptake and glycolysis. Akt-dependent glucose up-
take and lactate production were completely blocked in the
presence of rapamycin (Figure 1C). Likewise, we observed a re-
duction in Akt-dependent amino acid uptake and cellular amino
acid content by rapamycin treatment (Figure S2). Analysis of in-
corporation of radioactive glucose, pyruvate, or acetate into cel-Cell Mlular lipids showed that Akt activation leads to a substantial
increase in glucose-dependent lipogenesis. Crucially, this was
completely blocked by rapamycin treatment (Figure 1D), indicat-
ing that activation of de novo lipid synthesis by Akt requires
mTORC1 function.
We have previously shown that Akt induces accumulation of
intracellular lipids including phosphoglycerides (Porstmann
et al., 2005). Figure 1E shows that inhibition of mTORC1 by rapa-
mycin prevents Akt-dependent accumulation of unsaturated
(UFA) and saturated fatty acids (FA) as well as phosphatidylcho-
line (PC) and phosphatidylglycerol (PG) levels (Figure 1E).
We next asked whether induction of lipid biosynthesis is re-
quired for Akt-dependent increase in cell size. Fatty acid biosyn-
thesis requires cytoplasmic acetyl-CoA, which is generated by
the enzyme ATP-citrate lyase (ACLY). ACLY function is required
for tumor growth in vivo (Bauer et al., 2005; Hatzivassiliou et al.,
2005). Inhibition of ACLY using the inhibitor SB204990 attenu-
ated Akt-dependent increase in cell volume in RPE cells (Figures
1F and 1G).
Activation of SREBP1 by Akt
Studies in knockout mice have shown selective involvement of
SREBP1a and 1c in the regulation of lipid biosynthesis (Liang
et al., 2002) and promoters of lipogenic genes are preferentially
bound by SREBP1a in vivo (Bennett et al., 2004). Mature
SREBP1 can be detected in nuclear lysates as a diffuse band mi-
grating between 60 and 65 kDa. Figures 2A and 2B show that ac-
cumulation of nuclear mSREBP1 can be detected within 2 hr of
Akt activation. Induction of mSREBP1 precedes the increase in
full-length SREBP1 (flSREBP1), which can be detected after
8 hr of Akt activation (Figures 2A, 2B, and S3). An increase in
FASN mRNA and protein expression can be detected after
4 and 8 hr of Akt activation, respectively (Figures 2C and 2D).
Induction of nuclear mSREBP1 as well as FASN expression in re-
sponse to Akt activation is blocked by sterols (Figures 2E and
2F). Sterols induce a conformational change in SCAP that in-
duces INSIG binding, thereby preventing ER/Golgi translocation
of the SREBP/SCAP complex and SREBP processing (Sun et al.,
2005). The observed induction of flSREBP in response to sterol
treatment is most likely due to activation of the liver X receptor
(LXR) (Repa et al., 2000) (Figure 2F).
Akt induces glucose uptake by inducing glucose transporter
expression and membrane localization, and enhances glycolytic
activity by activating hexokinase (Manning and Cantley, 2007).
We next asked whether glucose is required for Akt-dependent
activation of SREBP1. Absence of glucose or treatment with 2-
deoxyglucose, an inhibitor of glycolysis, blocked Akt-dependent
accumulation of mSREBP1 (Figure 2G) and prevented induction
of SREBP target genes (Figure 2H). Energy depletion after glu-
cose starvation or inhibition of glycolysis is likely to lead to acti-
vation of AMPK (Hardie and Carling, 1997). Activation of AMPK
by AICAR also blocked accumulation of mSREBP1 in response
to Akt activation (Figure 2I) and prevented induction of SREBP
target genes (Figure S4). These results indicate that activation
of SREBP1 by Akt is regulated by cellular energy status.
SREBP1 Activation and Lipogenesis Require mTORC1
The activity of mTORC1 is regulated by growth factor signal-
ing as well as nutrient availability and energy homeostasisetabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc. 225
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Role of SREBP in Akt-Dependent Cell GrowthFigure 1. mTORC1 Is Required for Akt-Dependent Cell Growth and Induction of Lipid Synthesis
(A) RPE myrAkt-ER cells were treated with 100 nM 4-hydroxytamoxifen (4-OHT) or solvent (ethanol) for 24 hr in medium with 1% lipoprotein deficient serum
(LPDS) in the presence or absence of 50 nM rapamycin. In (A), cell size was determined by measuring electronic cell volume.
(B) Changes in median cell volume (MCV) induced by Akt activation relative to solvent control.
(C) RPE myrAkt-ER cells were treated with ethanol (dark gray bars), 4-OHT (black bars), rapamycin (open bars), or rapamycin and 4-OHT (light gray bars) for 48 hr
in medium containing 1% LPDS. Glucose uptake and lactate production was determined by measuring metabolite concentrations in culture supernatant using
NMR spectroscopy. Metabolite levels were normalized to cell number and compared to medium without cells. Values represent mean percent changes relative to
ethanol-treated cells. (*) p% 0.01 ethanol versus 4-OHT.
(D) RPE myrAkt-ER cells were treated as in (A), and incorporation of D-[6-14C]glucose, [2-14C]-pyruvate, and [1-14C]-acetate into cellular lipids was measured.226 Cell Metabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc.
Cell Metabolism
Role of SREBP in Akt-Dependent Cell GrowthFigure 2. Akt Induces Rapid Accumulation
of mSREBP1 in the Nucleus
(A) RPE myrAkt-ER cells were cultured in medium
with 1% LPDS for 16 hr and treated with 100 nM 4-
OHT for the indicated times. Nuclear extracts were
prepared and analyzed for expression of mature
SREBP1 (mSREBP1). Full-length SREBP1
(flSREBP) was detected in the supernatant.
(B) Quantitative representation of levels of mature
and flSREBP1 in response to Akt activation in RPE
cells.
(C and D) Cells were treated with 100 nM 4-OHT
for the indicated times. Relative mRNA abundance
of FASN was determined by qPCR. Values are nor-
malized to GAPDH and are shown relative to sol-
vent treated control. A representative of two inde-
pendent experiments performed in duplicate is
shown (D). Whole cell lysates prepared from cells
treated in parallel to (C) were used to determine
abundance of FASN, flSREBP1, and phospho-
Akt-ER.
(E) Cells were cultured in medium with 1% LPDS
and treated with 100 nM 4-OHT or solvent in the
presence or absence of a mixture of 10 mg/ml cho-
lesterol and 1 mg/ml 25-hydroxycholesterol (ste-
rols) for 2 hr, and nuclear extracts were analyzed
for expression of mSREBP1.
(F) Cells were treated with 100 nM 4-OHT in the
presence or absence of sterols for 24 hr. Whole
cell lysates were analyzed for expression of
FASN, flSREBP1, and phospho-Akt-ER.
(G) Cells were cultured in medium with 1% LPDS
for 16 hr and then placed in glucose-free medium
or medium containing 2.5 mM glucose. Cells were
treated with 2-deoxy-glucose (2-DG) and 4-OHT
as indicated. Nuclear extracts were prepared
and analyzed for the presence of mSREBP1.
(H) Cells were placed in glucose-free medium con-
taining 1% LPDS or medium supplemented with
2.5 mM glucose or glucose and 2-DG for 30 min
prior to stimulation with 100 nM 4-OHT for 24 hr.
Whole cell lysates were analyzed for expression
of FASN and full-length SREBP1.
(I) Cells were treated with 4-OHT for 2 hr with or
without pretreatment with AICAR for 30 min. Nu-
clear extracts were analyzed for the presence of
mSREBP1. Error bars represent SD.(Sarbassov et al., 2005). We therefore tested whether the
regulation of SREBP1 by Akt involves mTORC1. Nuclear accu-
mulation of mSREBP1 in response to Akt activation was pre-
vented by rapamycin (Figure 3A). Likewise, induction of FASN
and ACLY mRNA and protein levels was blocked by rapamy-
cin treatment (Figures 3B and 3C). Importantly, treatment with
rapamycin completely abolished induction of phosphorylation
of the ribosomal protein S6, but only had a minor effect onCell Mphosphorylation of GSK3 or ACLY, indicating that the activity
of the myrAkt-ER fusion protein is not affected by rapamycin
(Figure 3C). Furthermore, rapamycin treatment also blocked
insulin-dependent induction of FASN protein and mRNA
(Figures S5A and S5B) and ectopic expression of mTOR
was sufficient to induce mSREBP1 as well as FASN expres-
sion in the absence of myrAkt-ER activation in U2OS cells
(Figure S5C).(E) Cellular lipids were extracted from cells treated as in (C) and analyzed by NMR spectroscopy. Metabolite concentrations were normalized to cell number and
values represent mean percent changes relative to ethanol treated cells. (*) p < 0.01 ethanol versus 4-OHT; (**) p < 0.05 4-OHT versus 4-OHT plus rapamycin. UFA,
unsaturated fatty acids; FA,saturated fatty acids; PE = phosphatidylethanolamine; PC = phosphatidylcholine; PG = phosphatidylglycerol.
(F) RPE myrAkt-ER cells were stimulated with 4-OHT for 24 hr in the presence or absence of 60 mM SB20490, and cell volume was determined.
(G) Changes in MCV after activation of Akt in the presence or absence of 60 mM SB20490. In (B), (D), and (G), error bars represent standard deviation (SD). In (C)
and (E), error bars represent standard error of the mean (SEM).etabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc. 227
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Role of SREBP in Akt-Dependent Cell GrowthMature SREBP proteins are highly unstable and are rapidly de-
graded through an ubiquitin-dependent pathway (Hirano et al.,
2001). It has been shown that mSREBP can be phosphorylated
by GSK3. This phosphorylation enables binding of the Fbw7
ubiquitin ligase and induces degradation of the SREBP protein.
We next asked whether Akt affected the stability of mSREBP.
Activation of Akt increased levels of transfected myc-tagged
wild-type mSREBP1 (amino acids 1–490) (Figure 3D). This effect
was abolished when two phosphorylation sites for GSK3 were
mutated to alanine. Interestingly, Akt-dependent accumulation
of exogenous wild-type mSREBP could still be observed in the
presence of rapamycin, indicating that mTORC1 function is dis-
pensable for stabilization of mSREBP1 in response to Akt activa-
Figure 3. Akt-Dependent Activation of
SREBP1 and Lipogenesis Requires
mTORC1 Activity
(A) RPE-myrAkt-ER cells were cultured in medium
with 1% LPDS for 16 hr and treated with 100 nM 4-
OHT for 2 hr with or without pretreatment with
50 nM rapamycin for 30 min. Nuclear extracts
were prepared and analyzed for expression of of
mSREBP1.
(B) Cells were cultured in medium with 1% LPDS
and treated with 100 nM 4-OHT or solvent for
24 hr in the presence or absence of 50 nM rapamy-
cin. Total RNA was extracted and analyzed by
qPCR for expression of ACLY and FASN. Values
are normalized to GAPDH and are representative
of one of three independent experiments.
(C) Whole cell lysates of cells treated as in (B) were
used to determine the abundance of FASN, ACLY,
and flSREBP1 as well as phosphorylation of ACLY
and GSK3a/b.
(D) Cells were transfected with 1 mg of expression
vector for myc-SREBP1 (aa 1-490) wild-type or the
T426A/S430A mutant. 24 hr post-transfection,
cells were placed in medium containing 1%
LPDS and treated with 100 nM 4-OHT or solvent
in the presence or absence of 50 nM rapamycin
for 24 hr. Abundance of myc-mSREBP1 was de-
termined using the 9E10 antibody.
(E) Cells were transfected with 100 nM siRNA oli-
gonucleotides specific for SREBP1 and SREBP2
(BP1+BP2), mTOR, raptor, rictor or an unspecific
control. 72 hr post-transfection, cells were placed
in medium containing 1% LPDS and treated with
4-OHT for 24 hr. Lysates were used to confirm si-
lencing efficiency and to determine FASN and
ACLY expression.
(F) Cells treated in parallel to (E) were used to de-
termine incorporation of D-[6-14C]glucose,
[2-14C]-pyruvate or [1-14C]-acetate into lipid frac-
tions. Error bars represent SD.
tion. Furthermore, inhibition of GSK3 us-
ing the chemical inhibitor SB216763 did
not block Akt-dependent accumulation
of endogenous mSREBP1, induction of
FASN protein, or FASN promoter activity
in response to Akt activation (Figure S6).
These results indicate that Akt-depen-
dent activation of endogenous SREBP
does not solely involve regulation of the stability of SREBP but
suggest an additional, mTORC1-dependent pathway that
contributes to SREBP activation.
It has previously been suggested that rapamycin treatment can
also affect the activity of mTORC2 in certain cell types (Sarbassov
et al., 2006). Our own results show that long-term treatment with
rapamycin leads to activation of Akt phosphorylation by inhibition
of a negative feedback loop in the cell line used here (Figure S7).
To address any potential involvement of mTORC2 in the regula-
tion of lipogenic gene expression, we used siRNA to selectively
abolish expression of raptor or rictor, components of mTORC1
or mTORC2, respectively. Silencing of mTOR and raptor signifi-
cantly reduces S6 phosphorylation (Figure 3E), while rictor228 Cell Metabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc.
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Role of SREBP in Akt-Dependent Cell GrowthFigure 4. Silencing of SREBP1 Restricts Akt-Induced Cell Growth in Mammalian Cells
(A) RPE-myrAkt-ER cells were transfected with either 50 or 100 nM siRNA oligonucleotides specific for SREBP1 and SREBP2 (BP1 + BP2) or an unspecific con-
trol. Seventy-two hours post transfection, cells were placed in medium containing 1% LPDS and treated with 100 nM 4-OHT or solvent for 24 hr, and cell size was
determined.
(B) Changes in median cell volume (MCV) following Akt activation relative to solvent control.
(C) Whole cell lysates of cells treated in parallel to (A) were used to determine levels of FASN, SREBP1, SREBP2 and phospho-Akt-ER. Error bars represent SD.silencing results in reduction of Akt phosphorylation on threonine
450 (Figure S8), which has been shown to be a substrate for
mTORC2 (Facchinetti et al., 2008; Ikenoue et al., 2008). Silencing
of mTOR or raptor, but not rictor, prevents Akt-dependent induc-
tion of FASN and SREBP1 expression (Figure 3E). Expression of
SREBP2 was not affected by silencing of mTORC1 or mTORC2
components. Silencing of mTOR also blocked Akt- dependent
FASN and ACLY induction in U2OS cells (Figure S9). We also ad-
dressed the role of SREBP in the induction of de novo lipid bio-
synthesis in response to Akt activation. Figure 3F shows that si-
lencing of SREBP1 and 2 blocks incorporation of glucose,
pyruvate, or acetate into cellular lipids. Furthermore, silencing
of mTOR or raptor, but not rictor, abolished induction of lipogen-
esis in response to Akt activation (Figure 3F).
SREBP Is Required for Cell Growth in Mammalian Cells
We next asked whether induction of lipogenic gene expression
by SREBP is involved in the regulation of cell growth in mam-Cell Mmalian cells. Transfection of siRNA oligonucleotides targeting
both SREBP1 and 2 significantly reduced the increase in cell
size observed in response to Akt activation in RPE cells in
a dose-dependent manner (Figures 4A and 4B). Likewise, in-
duction of FASN expression in response to Akt activation was
reduced when SREBP1 and 2 were silenced (Figure 4C). Similar
results were obtained when SREBP1 and 2 were silenced using
different siRNA sequences (data not shown). These results indi-
cate that activation of SREBP and expression of SREBP target
genes is required for efficient cell growth in mammalian cells
in vitro.
Role of SREBP in Cell and Organ Size Control
in Drosophila
HLH106 has been identified as the gene coding for a single
SREBP isoform in flies, and dSREBP shows significant
sequence homology to human SREBP1 within its DNA binding
domain (Seegmiller et al., 2002).etabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc. 229
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Role of SREBP in Akt-Dependent Cell GrowthWe first measured the effect of transient silencing of dSREBP
or dFAS on cell volume in the Drosophila cell line Kc167. Figures
5A and 5B show that silencing of dSREBP or dFAS results in
a significant reduction in mean cell volume and FSC of G1 cells.
Simultaneous silencing of TSC2 did not rescue the observed re-
duction in cell size. Interestingly, insulin treatment of Kc167 cells
resulted in increased levels of fatty acids and phosphoglycerides
similar to the results obtained upon Akt activation in mammalian
cells (Figure S10).
To address the role of dSREBP in the regulation of cell growth
in vivo, we generated a series of transgenic flies expressing an in-
verted repeat RNA under the control of the UAS promoter. Three
Figure 5. Silencing of dSREBP Reduces
Cell and Organ Size in Drosophila
(A) Kc167 cells were treated with dsRNAs corre-
sponding to GFP, dSREBP, or dFAS in the ab-
sence or presence of dTSC2 dsRNA for 5 days,
and electronic cell volume was determined.
(B) Cells treated as in (A) were used to determine
FSC-A of the G1 population by FACS.
(C) dSREBP RNAi was expressed ubiquitously
during embryogenesis using the daughterless-
GAL4 (da-GAL4) driver. Expression of dSREBP
(white bars) and dFAS (gray bars) in second instar
larvae was determined by qPCR. Transcript levels
are normalized to actin mRNA levels and represent
three independent experiments. (RNAi-S1, single
insertion, RNAi-S2 and RNAi-S3, double inser-
tions).
(D) Representative phenotype of female flies ex-
pressing dSREBP RNAi using the da-GAL4 driver
compared to control (yw).
(E) Wings of flies expressing dSREBPRNAi-S3 in the
dorsal cell layer of the wing.
(F)Wing area analysis ofcontrol (yw), dSREBPRNAi-S1,
dSREBPRNAi-S2, and dSREBPRNAi-S3. (*) p% 105.
(G) Wings of flies expressing dSREBPRNAi-S3 in the
posterior compartment of the developing wing.
(H) Changes in wing area of control flies (white bars)
or flies expressing SREBP RNAi-2 (gray bars) or
SREBP RNAi-3 (black bars) in the posterior com-
partment of the wing. (*) p% 108.
(I) High-magnification images of the anterior and
posterior compartments of wings shown in (G).
(J) Changes in wing epithelial cell number of flies
expressing GFP (white bars) or dSREBPRNAi-S3
(black bars) in posterior compartment of the
wing. Error bars represent SD.
different fly lines (RNAi-S1, RNAi-S2, and
RNAi-S3) were used for the analysis. In-
duction of dSREBP RNAi expression us-
ing the daughterless (da)-GAL4 driver re-
sulted in reduced expression of dSREBP
and dFAS in larvae (Figure 5C). The three
RNAi lines showed differences in silenc-
ing efficiency with RNAi-S3 having the
strongest effect (Figure 5C). Silencing of
dSREBP during embryogenesis caused
a dose-dependent developmental delay
and lethality during larval and pupal
stages (Figure S11). Flies reaching adulthood showed a signifi-
cant reduction in body size, reduced body weight, and wing
area (Figures 5D and S12). The RNAi-S3 fly line did not produce
any viable offspring when crossed to the da-GAL4 driver. This
is consistent with an essential role of dSREBP during larval devel-
opment (Kunte et al., 2006).
Deletion or overexpression of components of the insulin sig-
naling pathway affects cell size in a cell-autonomous manner
(Weinkove et al., 1999). We therefore asked whether silencing
of dSREBP in specific compartments of the Drosophila wing
could affect cell and organ size. Figures 5E and 5F show
that expression of dSREBP RNAi cassette in the dorsal wing230 Cell Metabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc.
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Role of SREBP in Akt-Dependent Cell Growthcompartment (MS1096-GAL4) caused a dose-dependent re-
duction in adult wing area. Similarly, silencing of dSREBP us-
ing the engrailed (en)-GAL4 driver caused a specific reduction
in the area of the posterior compartment of the wing (Figures
5G and 5H). Furthermore, reduced size of the posterior com-
partment was accompanied by an increase in density of
wing epithelial cells (Figures 5I and 5J) indicating that silencing
of dSREBP causes a reduction in cell size. We also investi-
gated whether inhibition of dSREBP function by means other
than gene silencing would cause similar growth inhibition. De-
letion of the N-terminal transactivation domain in mammalian
SREBP results in dominant inhibition of SREBP function
(Sato et al., 1994). MS1096-GAL4-driven expression of N-ter-
minally deleted dSREBP (DN75) or a mutant in which the
transmembrane domain has been deleted in addition to the
Figure 6. dSREBP Is Regulated by the PI3K
Pathway and Required for dp110-Depen-
dent Cell Growth
(A) Kc167 cells were treated with dsRNAs corre-
sponding to GFP, dSREBP, dFAS, dp110, dAKT,
and dPTEN for 5 days. Expression of dSREBP
(white bars) and dFAS (gray bars) was determined
by qPCR. Values are normalized to actin mRNA
levels and show a representative of three experi-
ments performed in duplicate.
(B) Second instar larvae expressing dp110 ubiqui-
tously throughout development were analyzed for
dSREBP (white bars) and dFAS (gray bars) by
qPCR. Values are normalized to actin mRNA
levels.
(C) Flies expressing fl-dSREBP or m-dSREBP un-
der the control of the UAS promoter (UAS-fl-
dSREBP1) were crossed with flies expressing
GAL4 (MS1096-G4) or dp110 and GAL4 in the dor-
sal cell layer of the wing (MS1096-G4-UAS-
dp110). Representative individual flies are shown.
Arrows indicate severe malformation of the wing.
(D) Wing size analysis of flies expressing
dSREBPRNAi-S2 or dSREBPRNAi-S3 with (MS1096-
G4-UAS-dp110) or without (MS1096-G4) coex-
pression of dp110. nR 7 wings; (*) p% 5 3 108.
(E) Quantification of wing area of flies expressing
dSREBPRNAi-S3 with (dpp-G4-UAS-dp110[KD]) or
without (dpp-G4) coexpression of kinase-dead
dp110. Error bars represent SD.
N terminus (DN75T) resulted in a substan-
tial reduction in wing area (Figure S13).
SREBP Is a Target of the PI3K
Pathway in Drosophila
We next asked whether the PI3K/Akt
pathway regulates the activity of SREBP
in flies. Transient silencing of the catalytic
subunit of PI3K, dp110, or dAkt reduced
mRNA abundance of dFAS and dSREBP
in Kc167 cells (Figure 6A). Conversely,
silencing of dPTEN resulted in increased
expression of both transcripts (Figure
6A). Ubiquitous expression of dp110 us-
ing the da-GAL4 driver resulted in en-
hanced dSREBP and dFAS expression in second instar larvae
compared to controls (Figure 6B), indicating that the PI3K/Akt
pathway activates dSREBP function.
Expression of mature dSREBP (m-dSREBP) using the
MS1096-GAL4 driver resulted in significant lethality when flies
were reared at 25C (data not shown). When flies were reared
at 18C (resulting in a reduced activity of the GAL4/UAS system),
severe deformation of the wing was observed (Figure 6C). Ex-
pression of the full-length form of dSREBP (fl-dSREBP) in the
wing caused less severely misshapen wings even when flies
were reared at 25C. However, coexpression of dp110 and
full-length dSREBP resulted in severely deformed wings, a phe-
notype that is similar to that caused by expression of m-dSREBP
(Figure 6C). This result suggests that the activity of full-length
dSREBP is enhanced by PI3K signaling.Cell Metabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc. 231
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wing, indicated by a 15%–20% increase in surface area of the
wing (Leevers et al., 1996; Radimerski et al., 2002) (Figure 6D).
Silencing of dSREBP attenuated the increase in wing size in-
duced by expression of dp110 (Figure 6D). Similar results were
obtained using a nonoverlapping RNAi sequence targeting
dSREBP or by heterozygous deletion of the dSREBP gene
(Figure S14).
Expression of a kinase domain mutant of PI3K (dp110[KD])
decreases cell and organ size in Drosophila (Leevers et al.,
1996). Expression of dp110[KD] using the decapentaplegic
(dpp)-GAL4 driver resulted in a 20%–30% reduction in the size
of the dpp compartment. Expression of the dSREBP RNAi hairpin
resulted ina smallbut significantdecrease inwingarea (Figure6E).
However, coexpression of dSREBP RNAi with dp110KD did not
further decrease the size of this compartment. (Figure 6E). Taken
together, these results suggest that dp110 and dSREBP are com-
ponents of the same pathway in the regulation of cell growth in
Drosophila.
DISCUSSION
Cell growth is tightly controlled by mitogenic signaling pathways
and requires the activation of biosynthetic pathways for the gen-
eration of macromolecules, including proteins and lipids. Activa-
tion of the mTOR complex 1 (mTORC1) increases translation and
ribosome biogenesis (Wullschleger et al., 2006), but effects of
mTORC1 on other anabolic processes are less well understood.
We show here that ectopic activation of Akt induces a signifi-
cant increase in cell volume in the absence of mitogens and that
Akt-dependent size increase is blocked by the mTORC1 inhibitor
rapamycin. Analysis of medium metabolites by NMR revealed
that Akt activation results in increased uptake of glucose and
amino acids as well as secretion of lactate. The involvement of
mTORC1 in Akt-dependent translocation of glucose and amino
acid transporters to the plasma membrane has been demon-
strated before (Edinger and Thompson, 2002). We observed sig-
nificant accumulation of fatty acids and phosphoglycerides in
response to Akt activation and enhanced incorporation of la-
beled glucose, pyruvate, or acetate into the lipid fraction in cells
with activated Akt, all of which was blocked by rapamycin. These
results show that Akt activates de novo lipogenesis and that
mTORC1 activity is required for this effect.
Hepatocytes show increased SREBP1c mRNA levels in re-
sponse to insulin treatment or Akt expression (Azzout-Marniche
et al., 2000; Fleischmann and Iynedjian, 2000). We have previ-
ously shown that Akt activation results in nuclear accumulation
of mSREBP1 and enhances expression of a number of SREBP
target genes (Porstmann et al., 2005). Here, we show that
nuclear accumulation of mSREBP1 is rapid and precedes the
induction of transcription of SREBP target genes as well as the
increase in flSREBP1. It should be noted that the srebf1 gene
is a target of positive feed-forward regulation, since a functional
SRE has been identified in its promoter region (Amemiya-Kudo
et al., 2000). Thus, induction of flSREBP after Akt activation
could be due to enhanced SRE-dependent transcription of the
gene. Activation of SREBP1 by Akt was completely blocked by
glucose starvation, inhibition of glycolysis, or AMPK activation
by AICAR. AMPK is activated by an increase in AMP/ATP ratio232 Cell Metabolism 8, 224–236, September 3, 2008 ª2008 Elsevierfollowing energy deprivation. AMPK regulates lipid metabolism
by phosphorylating ACC and induces a switch from fatty acid
biosynthesis to fatty acid oxidation (Hardie and Carling, 1997).
Thus, regulation of SREBP activity by AMPK could reflect an ad-
ditional adaptation to energy restriction.
Activity of mTORC1 is regulated by mitogens but also re-
sponds to cellular energy status (Sarbassov et al., 2005).
AMPK activates TSC2 resulting in inhibition of mTORC1 (Inoki
et al., 2003). It seems likely that inhibition of SREBP1 activity fol-
lowing glucose deprivation or AMPK activation is mediated by
mTORC1. Our results show that nuclear accumulation of
SREBP1 and induction of SREBP target genes requires
mTORC1 activity. It has been suggested that induction of
FASN and ACC expression by Her2 in breast cancer cells in-
volves increased protein translation (Yoon et al., 2007). However,
we observed an increase in FASN and ACLY mRNA abundance
in response to Akt activation. Induction of FASN and ACLY
mRNA was blocked in the presence of rapamycin indicating
that mTORC1 is involved in the regulation of SREBP-dependent
transcription. Furthermore, silencing of mTOR or raptor, but not
rictor, abolished activation of expression of SREBP1, FASN, and
ACLY, thus confirming that regulation of SREBP-dependent
gene expression is exclusive to mTORC1.
It has been shown that GSK3 regulates the stability of
mSREBP1 by inducing the association of the ubiquitin ligase
Fbw7 resulting in rapid degradation of SREBP1 (Sundqvist
et al., 2005). We observed an increase in the stability of exoge-
nous mSREBP in response to Akt activation. This was depen-
dent on the presence of two GSK3 phosphorylation sites but
was still observed in the presence of rapamycin. It therefore
seems likely that Akt regulates SREBP activity in at least two
ways. Akt increases the stability of mSREBP1 by inhibiting
GSK3-dependent phosphorylation. However, our results indi-
cate that Akt also regulates SREBP1 activity in a GSK3-indepen-
dent, mTORC1-dependent manner. It has been shown that dom-
inant negative Akt prevents ER/Golgi translocation of SCAP (Du
et al., 2006). TOR has been implicated in vesicle transport in
yeast (Neufeld, 2007) and localization of mTOR to the ER and
the Golgi plays an essential role in its regulation and downstream
signaling (Drenan et al., 2004). Thus, it seems possible that
mTORC1, or proteins downstream of mTORC1 signaling such
as S6K or 4-EBP, could be involved in the regulation of SREBP
processing within these compartments.
Our results clearly implicate mTORC1 in the regulation of lipo-
genesis in epithelial cells. Silencing mTOR or raptor, but not
rictor, is sufficient to abolish Akt-dependent incorporation of glu-
cose, pyruvate, or acetate into cellular lipids. This effect seems
to be most pronounced for the incorporation of acetate, which
only requires the activity of ACC and FASN. An involvement of
raptor in the regulation of lipogenesis is also consistent with its
essential function during mouse development (Guertin et al.,
2006). Interestingly, silencing of SREBP1 and 2 was sufficient
to prevent Akt-dependent lipogenesis and significantly reduced
cell growth in response to Akt activation. This result confirms that
SREBP-dependent gene expression represents an important
mechanism in the regulation of lipogenesis during cell growth.
Consistent with a role for SREBP in cell size regulation in mam-
malian cells, we observed that silencing of dSREBP or its target
gene dFAS resulted in a significant decrease in cell size inInc.
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completely blocked the increase in cell volume caused by silenc-
ing of TSC2. Silencing of dSREBP in different compartments of
the developing wing imaginal disc caused a reduction of the re-
spective compartment in adult flies and was caused by a reduc-
tion in cell size rather than cell number.
It is somewhat surprising that expression of m-dSREBP in the
wing causes a severe growth defect. It has been shown before
that overexpression of mSREBP1a causes cell-cycle arrest
through induction of the cdk inhibitors p21, p27, and p16 (Inoue
et al., 2005; Nakakuki et al., 2007). It is also possible that overac-
tivation of SREBP causes an imbalance between protein and
lipid biosynthesis and suggests that SREBP activity needs to
be tightly controlled to allow normal tissue development. Kunte
and coworkers have detected dSREBP activation in the devel-
oping fat body, the midgut as well as in oenocytes, a specialized
cell type that have hepatocyte-like functions in lipid metabolism
(Gutierrez et al., 2007; Kunte et al., 2006). This expression pat-
tern suggests a role in lipid metabolism similar to the function
of SREBP1c in mammalian liver. Our results are consistent
with a cell-autonomous role for dSREBP and suggest that
dSREBP is required for normal growth of peripheral larval tissue.
dSREBP silencing restricted tissue growth induced by overex-
pression of dp110 in the wing and did not enhance the reduction
in size of a wing compartment expressing kinase-dead dp110.
These results suggest that both factors are components of the
same pathway and indicate that activation of dSREBP is re-
quired for the induction of cell growth by the PI3K pathway in
Figure 7. Model of Regulation of Lipid Biosynthesis by Akt and
mTORC1
Akt and mTORC1 regulate lipid biosynthesis on several levels. Activation of
glucose uptake and induction of glycolysis is required for the generation of
mitochondrial citrate. Activation of SREBP1 by Akt induces the expression
of enzymes involved in lipid biosynthesis, including ACLY, FASN, and ACC.
Akt stabilizes mSREBP1 by inhibition of GSK3. Inhibition of mTORC1 blocks
accumulation of mSREBP1 in response to Akt activation through an unknown
mechanism.Cell Mflies. It will be interesting to investigate whether regulation of
dSREBP downstream of PI3K requires TOR. Further investiga-
tions are required to elucidate the exact mechanism of regulation
of dSREBP activity by signaling pathways involved in growth
regulation in flies.
Taken together, our data are consistent with a model that pla-
ces SREBP activation downstream of the intracellular signaling
pathway that integrates mitogenic signaling with energy status
and nutrient availability (Figure 7). It also suggests that protein
biosynthesis and lipogenesis are regulated in a concerted man-
ner during cell growth.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
RPE myrAkt-ER and U2OS myrAkt-ER cells have been described before
(Porstmann et al., 2005). RPE myrAkt-ER cells were maintained in DMEM/
HAMS F12 (1:1) medium with 10% FCS, glutamine, and sodium bicarbonate.
U2OS myrAkt-ER cells were grown in DMEM with 10% FCS and glutamine. For
culture at low sterol concentration, cells were grown in medium with 1% lipo-
protein deficient serum (LPDS, Intracel). Kc167 cells were cultured in
Schneider’s medium (GIBCO) with 10% FCS, penicillin/streptomycin, and
glutamine. A list of antibodies, chemicals, and plasmids is provided in the Sup-
plemental Experimental Procedures.
Cell Size Determination and Flow Cytometry
RPE myrAkt-ER cells were detached using trypsin, washed, and resuspended
in PBS. Median electronic cell volumes were determined in triplicate using a Z2
Coulter Counter (Multisizer II, Beckman-Coulter). Kc167 cells were collected
by centrifugation and analyzed as above. For G1 specific cell size, KC167 cells
were fixed and stained with propidium iodide and G1-FSC was determined.
Experiments were repeated at least three times.
Metabolite Analysis
Two militers of culture medium samples were collected for the analysis of me-
tabolite concentrations. Four hundred and fifty microliters of medium samples
were mixed with 50 ml D2O, and 25 ml of 10 mM sodium TSP were added for
chemical shift calibration and quantification. Intracellular metabolites were ex-
tracted using a dual-phase-extraction method as previously described (Tyagi
et al., 1996). Lipid extracts were reconstituted in 600 ml deuterated chloroform,
and 0.008% v/v tetramethylsilane was used as a chemical shift reference
(0 ppm). Water-soluble metabolites were reconstituted in 600 ml D2O, and
25 ml of 1 mM TSP was added for quantitation and chemical shift calibration.
Proton NMR spectra were acquired using a Bruker 600 MHz (Bruker Avance)
NMR system. Spectral peaks for water-soluble and lipid metabolites were
assigned according to Sitter et al. (2002) and Sze and Jardetzky (1990),
respectively. Metabolite levels were normalized to cell number, and each ex-
periment was repeated at least six times.
Lipid Synthesis
Cells were grown in medium with 1% LPDS in the presence of 100 nM 4-OHT
or ethanol for 24 hr. 2.5 mCi/ml D-[6-14C]glucose (45 mM final concentration,
Amersham), 2.5 mCi/ml [2-14C]-pyruvate (166 mM final concentration) or
10 mCi/ml [1-14C]-acetate (85 mM final concentration, both Perkin Elmer) was
added, and cells were incubated for 4 hr at 37C. Cell were washed three times
in PBS and lysed in 0.5% Triton X-100. Lipids were extracted by successive
addition of 2 ml methanol, 2 ml chloroform, and 1 ml dH2O. Phase separation
was achieved by centrifugation at 1000 rpm for 15 min. The organic (lower)
phase was recovered and dried. Lipids were dissolved in Ultima Gold LSC
Cocktail (Perkin Elmer) and counted on a Beckman LS 6500 scintillation
counter. Each measurement was performed in duplicate, results were normal-
ized to total protein content, and experiments were repeated at least twice.
Cell Lysis and Immunoblotting
For total cell lysis, cells were washed with ice-cold PBS and dissolved in lysis
buffer (1% Triton X-100, 50 mM Tris pH 7.5, 300 mM NaCl, 1 mM EGTA, 1 mMetabolism 8, 224–236, September 3, 2008 ª2008 Elsevier Inc. 233
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Role of SREBP in Akt-Dependent Cell GrowthDTT, 1 mM NaVO4, and Protease-Inhibitor [Roche]). Nuclear lysates were pre-
pared as described (Porstmann et al., 2005). For detection of mSREBP, cells
were treated with 25 mg/ml ALLN for 1 hr prior to lysis. Equal amounts of cell
lysates were separated on SDS-PAGE and blotted onto PVDF membrane (Im-
mobilon). Proteins were detected by immunoblotting with ECL detection.
RNA Preparation and Quantitative PCR
Total RNA was isolated from RPE myrAkt-ER or Kc267 cells using the RNeasy
kit (QIAGEN) and treated with DNase I (QIAGEN). For preparation of RNA from
Drosophila larvae, 10–20 s instar larvae were homogenized in liquid nitrogen
and dissolved in buffer RLT (QIAGEN) followed by RNA purification according
to manufacturer’s protocol. Two-and-a-half micrograms of total RNA was
used for first-strand cDNA synthesis with SuperScript II RT and oligo dT primer
(Invitrogen). Real-time PCR was performed with SYBR Green PCR Master Mix
(Applied Biosystems). All reactions were performed at least in duplicate.
Primer sequences are provided in the Supplemental Experimental Procedures.
Transfection and RNA Interference
RPE-myrAkt-ER cells were transfected using Fugene (Roche) according to
manufacturer’s instructions. Twenty-four hours post transfection, cells were
placed into medium containing 1% LPDS and induced with 100 nM 4-OHT
as indicated.
For gene-silencing experiments, cells were transfected using DharmaFECT
reagent 1 (Dharmacon) following a reverse transfection protocol. Twenty-four
hours post transfection, cells were split and divided into parallel cultures for
different treatments. SiRNA sequences are provided in the Supplemental
Experimental Procedures.
For depletion experiments in Kc167 cells, dsRNAs were generated by in vitro
transcription using the MEGASCRIPT T7 transcription kit (Ambion). Primer se-
quences are provided in the Supplemental Experimental Procedures. Silenc-
ing was performed using 25 mg of dsRNA, and cells were analyzed after 5 days.
Transgenic Fly Lines
A sequence comprising 700 bp of the 50 end of the dSREBP gene was ampli-
fied by PCR from genomic DNA and inserted as an inverted repeat into pWIZ-
UAST (Lee and Carthew, 2003). Transgenic flies were generated on a yw back-
ground. Single transgene insertions on chromosomes 2 and 3 were combined
to increase silencing efficiency. dSREBPRNAi-S1: one insertion, dSREBPRNAi-S2
and dSREBPRNAi-S3: two insertions.
UAS-Dp110WT, UAS-Dp110[KD], and dpp-GAL4/UAS-Dp110[KD] fly lines
were described previously (Weinkove et al., 1999). MS1096-GAL4/UAS-
Dp110WT flies were a gift from Ernst Hafen (ETH, Zuerich). dSREBP189 flies
were a gift from Robert B. Rawson (University of Texas Southwestern Medical
Center, Dallas). UAS-dSREBP fly lines were obtained from the Bloomington
Stock Center. The dSREBP RNAi line T1 was obtained form the Vienna Dro-
sophila RNAi Centre. Genotypes of all fly lines are provided in the Supplemen-
tal Experimental Procedures.
Analysis of Wing Area and Cell Number
Wings of male flies were dehydrated in ethanol, mounted in Euparal (Agar Sci-
entific), and photographed. Wing area was determined by measuring pixel
number. Cell number was determined by counting wing hairs in an area of fixed
size in anterior or posterior wing compartments. Unless stated, data represent
values generated from at least 20 wings of each genotype.
Statistical Analysis
P values were calculated using a two-tailed student’s t test assuming equal
variance.
SUPPLEMENTAL DATA
Supplemental Data include 14 figures and Supplemental Experimental Proce-
dures and can be found with this article online at http://www.cellmetabolism.
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